FDA Approved: LEQVIO — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for LEQVIO (inclisiran) filed by Novartis Pharmaceuticals Corporation, authorizing changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Familial Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• LEQVIO (inclisiran)

Snippet

SUPPL AP for LEQVIO (INCLISIRAN)